Nuvisertib (TP-3654), an investigational selective PIM1 kinase inhibitor, showed durable clinical response and sustained hematological improvement in relapsed/refractory myelofibrosis patients Meeting Abstract
| Authors: | El Chaer, F.; Rein, L. A. M.; Yuda, J.; Shimoda, K.; Takami, A.; Ichii, M.; McCloskey, J.; Scandura, J. M.; Iurlo, A.; Bose, P.; Haque, T.; Lucchesi, A.; Shirane, S.; Benevolo, G.; Amanam, I.; Kiladjian, J. J.; Vachhani, P.; Tantravahi, S. K.; Onishi, Y.; Rinaldi, C.; Rotta, M.; Granacher, N.; Patel, A. A.; Loschi, M.; Alimam, S.; Bradley, T.; Cheung, S.; Ribrag, V.; Kabir, S.; Ansaldo, K.; Seki, M.; Loksa, V.; Li, Z.; Foulks, J. M.; Shah, J.; Rampal, R. |
| Abstract Title: | Nuvisertib (TP-3654), an investigational selective PIM1 kinase inhibitor, showed durable clinical response and sustained hematological improvement in relapsed/refractory myelofibrosis patients |
| Meeting Title: | 66th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 144 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Dec 7-10 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2024-11-05 |
| Start Page: | 655 |
| End Page: | 657 |
| Language: | English |
| ACCESSION: | WOS:001415676400004 |
| DOI: | 10.1182/blood-2024-200312 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
